Want to see MYGN full AI Analyst Report?
Volume Changes by Segment
Tracks the number of tests, orders, or prescriptions in each business segment over time, exposing true demand trends that revenue can mask. Rising volumes indicate growing patient adoption and market share, while falling volumes point to weaker uptake, reimbursement pressure, or increased competition—early signals of future revenue direction.The large Q1 2026 jump into “Cancer Care Continuum” while hereditary and tumor profiling volumes drop to zero is most likely a reporting/reclassification move—not a sudden loss of tests—supported by management’s note of double‑digit hereditary growth and new MRD launches. Pharmacogenomics (GeneSight) momentum and improving ASPs reinforce underlying demand, but prenatal remains a persistent weakness. Key investor watchpoints: successful commercialization of MRD/Prolaris+, sales hires ramping to productivity, and payer reimbursement will determine whether back‑half revenue acceleration materializes.
Date | Hereditary Cancer | Tumor Profiling | Prenatal | Pharmacogenomics | Cancer Care Continuum |
|---|---|---|---|---|---|
Jun 30, 2026 | 0.00 | 0.00 | 144.00K | 140.00K | 95.00K |
Mar 31, 2026 | 0.00 | 0.00 | 153.00K | 136.00K | 96.00K |
Dec 31, 2025 | 82.00K | 12.00K | 150.00K | 138.00K | 0.00 |
Sep 30, 2025 | 82.00K | 12.00K | 155.00K | 137.00K | 0.00 |
Jun 30, 2025 | 78.00K | 12.00K | 159.00K | 135.00K | 0.00 |
Mar 31, 2025 | 73.00K | 12.00K | 173.00K | 127.00K | 0.00 |
Dec 31, 2024 | 76.00K | 12.00K | 159.00K | 127.00K | 0.00 |
Sep 30, 2024 | 74.00K | 13.00K | 162.00K | 127.00K | 0.00 |
Jun 30, 2024 | 73.00K | 14.00K | 173.00K | 129.00K | 0.00 |
Mar 31, 2024 | 71.00K | 14.00K | 172.00K | 124.00K | 0.00 |